Gilead Partners with Tubulis to Revitalize ADC Pipeline

Here is a rewritten version with a Title, keywords, and key facts:

Partnership Announcement:
Gilead Sciences has entered into a collaboration with Tubulis, a biotechnology company specializing in antibody-drug conjugates (ADCs), to enhance its ADC pipeline.

ADC Revival:
This partnership aims to revitalize Gilead's ADC program, which has faced challenges in recent years.

Tubulis Expertise:
Tubulis brings its proprietary technology and expertise in ADC development to the partnership, which is expected to accelerate Gilead's ADC pipeline.

Cancer Treatment Focus:
The collaboration will focus on developing ADCs for the treatment of various cancers, leveraging Tubulis' innovative approaches to improve ADC efficacy and safety.

Strategic Move:
This partnership is a strategic move by Gilead to strengthen its position in the oncology market and expand its portfolio of cancer treatments.